Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.50 (1.22%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Replacement - Result of AGM and Directorate Change

15 Dec 2023 18:12

RNS Number : 0565X
Frontier IP Group plc
15 December 2023

The following replaces the announcement "Result of Annual General Meeting and Directorate Change" released on 15 December 2023 at 14:07 under RNS No: 0306X.

Resolution 10 incorrectly stated : (i) 0 votes against- this has been corrected to 111; and (ii) total votes cast (excluding votes withheld) of 28,801,720- this has been corrected to 28,801,831.

Nothing else has been amended. The full corrected version is below.

RNS

AIM: FIPP

15 December 2023

Frontier IP Group Plc

("Frontier IP" or the "Group")

Result of Annual General Meeting and Directorate Change

Frontier IP, a specialist in commercialising intellectual property, announces that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed with the table below summarising proxy votes received.

The Company also confirms, as announced on 31 October 2023, that Andrew Richmond has not sought re-election as a director at today's annual general meeting and has stepped down from his role as Chairman with effect from today.

Dame Julia King, Baroness Brown of Cambridge has assumed the role of Chair following conclusion of today's AGM.

RESOLUTIONS

NO OF VOTES FOR

% OF VOTES CAST (EXCLUDING VOTES WITHELD)

NO OF VOTES AGAINST

% OF VOTES CAST (EXCLUDING VOTES WITHELD)

TOTAL VOTES CAST (EXCLUDING VOTES WITHHELD)

NO OF VOTES WITHHELD

ORDINARY

1. To receive the audited consolidated financial statements of the Company and its subsidiaries for the year ended 30 June 2023, together with the reports of the Directors and the Auditor thereon.

28,798,831

100%

0

0%

28,798,831

7,001

2. To approve the report of the Board to the members on directors' remuneration for the year ended 30 June 2023.

24,016,521

83%

4,761,258

17%

28,777,779

28,053

3. To re-appoint Neil Crabb as a Director of the Company and, being eligible, is offering himself for reappointment.

28,779,740

100%

3,000

0%

28,782,740

23,092

4. To re-appoint Jacqueline McKay as a Director of the Company and, being eligible, is offering herself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

5. To re-appoint James Fish as a Director of the Company and, being eligible, is offering himself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

6. To re-appoint Matthew White as a Director of the Company and, being eligible, is offering himself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

7. To re-appoint David Holbrook as a Director of the Company and, being eligible, is offering himself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

8. To re-appoint Nigel Grierson as a Director of the Company and, being eligible, is offering himself for reappointment

28,779,740

100%

0

0%

28,779,740

26,092

9. To re-appoint Professor Dame Julia King, Baroness Brown of Cambridge as a Director of the Company and, being eligible, is offering herself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

10. To resolve not to fill the vacancy created by the retirement of Andrew Richmond as a Director and Chairman of the Company at the AGM, in accordance with the Articles of Association of the Company

28,801,720

100%

111

0%

28,801,831

4,001

11. To re-appoint BDO LLP as auditor of the Company to hold office until the conclusion of the next general meeting at which financial statements are laid before shareholders.

28,797,617

100%

0

0%

28,797,617

8,215

12 To authorise the Directors to determine the auditor's remuneration

28,797,617

100%

4,214

0%

28,801,831

4,001

13. To authorise the directors to allot shares

28,779,740

100%

19,091

0%

28,798,831

7,001

SPECIAL

14. Authority to disapply pre-emption rights in connection with the allotment and issue of equity securities for cash in relation to (i) share option schemes; (ii) rights issue or similar offer; (iii) allotment of equity securities up to 10% of the issued share capital; or (iv) to the allotment of equity securities up to a nominal amount equal to 20%, such authority to be used only for the purposes of making a follow-on offer which the Board of the Company determines to be of a kind contemplated by paragraph 3 of Section 2B of the Statement of Principles on Disapplying Pre-Emption Rights.

23,213,401

81%

5,585,430

19%

28,798,831

7,001

15. Authority to disapply pre-emption rights to allot equity securities for cash.

27,929,775

97%

849,965

3%

28,779,740

26,092

16. Authority to purchase own shares on market.

24,461,860

100%

7,850

0%

24,469,710

4,336,122

Votes which have been cast at the discretion of the Chairman have been counted as votes for the resolutions. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution.

ENQUIRIES

Frontier IP Group Plc

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

T: 020 3968 7815

neil@frontierip.co.uk

M: 07464 546 025

andrew.johnson@frontierip.co.uk

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

T: 0203 328 5656

Singer Capital Markets (Broker)

Harry Gooden / James Fischer

T: 0207 496 3000

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCMZMMZRKGGFZM
Date   Source Headline
6th Dec 20196:25 pmRNSHolding(s) in Company
5th Dec 201912:00 pmRNSHolding(s) in Company
4th Dec 201912:00 pmRNSResult of AGM & Total Voting Rights
26th Nov 201912:58 pmRNSHolding(s) in Company
13th Nov 20195:00 pmRNSPosting of Annual Report and Accounts
7th Nov 201912:20 pmRNSHolding(s) in Company
6th Nov 20192:00 pmRNSResult of Placing
6th Nov 20197:01 amRNSProposed fundraising of £3.5m by way of Placing
6th Nov 20197:00 amRNSFinal Results
22nd Oct 20197:00 amRNSAppointment of senior advisers
15th Oct 20197:00 amRNSNew portfolio company: Elute Intelligence Holdings
10th Sep 20197:00 amRNSAppointment of Broker
25th Jul 20197:00 amRNSExscientia collaboration with Rallybio
15th Jul 201912:08 pmRNSHolding(s) in Company
14th Jun 20197:00 amRNSExscientia partnership with GT Apeiron
31st May 20195:00 pmRNSTotal Voting Rights
31st May 20193:15 pmRNSDirectorate Change
28th May 20197:00 amRNSFieldwork Robotics completes initial field trials
15th May 20197:00 amRNSDirector exercise of options, shareholding and TVR
10th May 201911:48 amRNSHolding(s) in Company
30th Apr 20197:00 amRNSEuropean plan to boost marine & coastal economies
8th Apr 20197:00 amRNSParkside Architectural Tiles launch Alusid range
8th Apr 20197:00 amRNSBosch UK to work with Pulsiv Solar
8th Apr 20197:00 amRNSInvestor event at the Royal Academy of Engineering
4th Apr 20197:00 amRNSExscientia reaches first major milestone with GSK
3rd Apr 20195:51 pmRNSHolding(s) in Company
3rd Apr 20193:45 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSFieldwork Robotics wins Innovate UK ISCF grant
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20197:00 amRNSBoard Appointment
27th Mar 20197:00 amRNSUnaudited Half Year Results
21st Mar 20199:18 amRNSTrading Update
21st Mar 20199:14 amRNSExscientia & Celgene drug discovery collaboration
6th Mar 20195:15 pmRNSHolding(s) in Company
20th Feb 20197:00 amRNSTVG - key partner in $9.67m DARPA project award
12th Feb 20197:00 amRNSThird Portuguese spin out: Insignals Neurotech
4th Feb 20197:00 amRNSAmprologix wins DHSC backing for new antibiotic
31st Jan 20199:00 amRNSNandi Proteins led consortium wins UK grant
25th Jan 20197:00 amRNSThe Vaccine Group wins Department of Health grant
7th Jan 20191:29 pmRNSExscientia Series B funding & Roche collaboration
27th Dec 20187:00 amRNSMolendotech - Palintest start commercial roll out
19th Dec 201811:45 amRNSResult of AGM
30th Nov 20185:30 pmRNSTotal Voting Rights
23rd Nov 201812:10 pmRNSPosting of Annual Report and Notice of AGM
22nd Nov 20181:12 pmRNSHolding(s) in Company
22nd Nov 201810:36 amRNSHolding(s) in Company
21st Nov 20183:30 pmRNSHolding(s) in Company
21st Nov 201811:00 amRNSTotal Voting Rights and Director/PDMR Shareholding
15th Nov 20184:08 pmRNSDirector Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.